From data to QSP models: a pipeline for using Boolean networks for hypothesis inference and dynamic model building

被引:0
作者
M. Putnins
O. Campagne
D. E. Mager
I. P. Androulakis
机构
[1] Rutgers University,Biomedical Engineering Department
[2] University at Buffalo,Department of Pharmaceutical Sciences
[3] State University of New York,Chemical & Biochemical Engineering Department
[4] Rutgers University,undefined
来源
Journal of Pharmacokinetics and Pharmacodynamics | 2022年 / 49卷
关键词
Boolean network; QSP; Dynamic models; Machine learning;
D O I
暂无
中图分类号
学科分类号
摘要
Quantitative Systems Pharmacology (QSP) models capture the physiological underpinnings driving the response to a drug and express those in a semi-mechanistic way, often involving ordinary differential equations (ODEs). The process of developing a QSP model generally starts with the definition of a set of reasonable hypotheses that would support a mechanistic interpretation of the expected response which are used to form a network of interacting elements. This is a hypothesis-driven and knowledge-driven approach, relying on prior information about the structure of the network. However, with recent advances in our ability to generate large datasets rapidly, often in a hypothesis-neutral manner, the opportunity emerges to explore data-driven approaches to establish the network topologies and models in a robust, repeatable manner. In this paper, we explore the possibility of developing complex network representations of physiological responses to pharmaceuticals using a logic-based analysis of available data and then convert the logic relations to dynamic ODE-based models. We discuss an integrated pipeline for converting data to QSP models. This pipeline includes using k-means clustering to binarize continuous data, inferring likely network relationships using a Best-Fit Extension method to create a Boolean network, and finally converting the Boolean network to a continuous ODE model. We utilized an existing QSP model for the dual-affinity re-targeting antibody flotetuzumab to demonstrate the robustness of the process. Key output variables from the QSP model were used to generate a continuous data set for use in the pipeline. This dataset was used to reconstruct a possible model. This reconstruction had no false-positive relationships, and the output of each of the species was similar to that of the original QSP model. This demonstrates the ability to accurately infer relationships in a hypothesis-neutral manner without prior knowledge of a system using this pipeline.
引用
收藏
页码:101 / 115
页数:14
相关论文
共 97 条
  • [1] Emmert-Streib F(2011)Networks for systems biology: conceptual connection of data and function IET Syst Biol 5 185-207
  • [2] Dehmer M(2009)Network analyses in systems pharmacology Bioinformatics 25 2466-2472
  • [3] Berger SI(2011)Role of systems pharmacology in understanding drug adverse events Wiley Interdiscip Rev Syst Biol Med 3 129-135
  • [4] Iyengar R(2016)Systems pharmacology–towards the modeling of network interactions Eur J Pharm Sci 94 4-14
  • [5] Berger SI(2009)Systems pharmacology and genome medicine: a future perspective Genome Med 1 11-571
  • [6] Iyengar R(2010)Diseases as network perturbations Curr Opin Biotechnol 21 566-504
  • [7] Danhof M(2012)Studying protein-protein interaction networks: a systems view on diseases Brief Funct Genomics 11 497-22
  • [8] Wist AD(2015)Drug target identification through systems biology Drug Discov Today Technol 15 17-25
  • [9] Berger SI(2020)Transitioning from basic towards systems pharmacodynamic models: lessons from corticosteroids Pharmacol Rev 72 1-53
  • [10] Iyengar R(2016)A model qualification method for mechanistic physiological QSP models to support model-informed drug development CPT: Pharmacometr Syst Pharmaco 5 43-160